The Journal of Urology最新文献_第2页

Kristen R. Scarpato, MD, MPH 克里斯汀·r·斯卡帕托，医学博士，公共卫生硕士

The Journal of Urology Pub Date : 2026-09-28 DOI: 10.1097/ju.0000000000005325

Kristen R. Scarpato

引用次数: 0

Challenging Problems, Meaningful Outcomes in Functional and Reconstructive Urology 功能性和重建泌尿外科的挑战问题和有意义的结果

The Journal of Urology Pub Date : 2026-09-24 DOI: 10.1097/ju.0000000000005313

D. Robert Siemens,Jonathan C. Routh

引用次数: 0

Eric C. Umbreit, MD Eric C. Umbreit， MD

The Journal of Urology Pub Date : 2026-09-17 DOI: 10.1097/ju.0000000000005316

Eric C. Umbreit

引用次数: 0

Age- and sex-specific prevalence of lower urinary tract symptoms and bowel dysfunction in children: Results from a National Survey 儿童下尿路症状和肠功能障碍的年龄和性别特异性患病率：来自一项全国调查的结果

The Journal of Urology Pub Date : 2026-09-10 DOI: 10.1097/ju.0000000000005303

Hiroshi Shimura,Kenji Omae,Yasuko Funabiki,Koki Sugimura,Ryota Furuya,Sachiko Tsuchiya,Ryosuke Suda,Takanori Mochizuki,Satoru Kira,Norifumi Sawada,Yoshiyuki Kojima,Yoshifumi Sugita,Takahiko Mitsui

引用次数: 0

“Focal Vapor Ablation of Prostate Cancer: Solid or Will It Evaporate With Time?” 前列腺癌局灶性气相消融：固体还是会随时间蒸发？

The Journal of Urology Pub Date : 2026-09-10 DOI: 10.1097/ju.0000000000005301

Savannah Starr,Wayne G. Brisbane,Scott Eggener

引用次数: 0

Efficacy and Tolerability of Overnight Bladder Drainage post Posterior Urethral Valve Ablation on Upper and Lower Urinary Tracts: A Randomized Controlled Trial. 上、下尿路后尿道瓣膜消融后膀胱引流的疗效和耐受性：一项随机对照试验。

The Journal of Urology Pub Date : 2026-07-21 DOI: 10.1097/ju.0000000000005226

Ahmed Elkashef,Ahmed Abdelhalim,Mohamed S Dawaba,Ashraf T Hafez

{"title":"Efficacy and Tolerability of Overnight Bladder Drainage post Posterior Urethral Valve Ablation on Upper and Lower Urinary Tracts: A Randomized Controlled Trial.","authors":"Ahmed Elkashef,Ahmed Abdelhalim,Mohamed S Dawaba,Ashraf T Hafez","doi":"10.1097/ju.0000000000005226","DOIUrl":"https://doi.org/10.1097/ju.0000000000005226","url":null,"abstract":"PURPOSETo study the effect of overnight bladder drainage (OBD) on upper and lower urinary tracts of boys post endoscopic valve ablation (EVA).MATERIALS AND METHODSIn a randomized controlled trial, boys who had persistent hydronephrosis (HN) and unfavorable bladder dynamics after EVA were included. Those who underwent urinary diversion, had residual obstruction or refused to participate were excluded. Patients were randomly allocated into OBD or no OBD groups. Timed voiding, anticholinergics and antibiotic prophylaxis were offered for all patients. After 12 months, patients were evaluated for HN, vesicoureteral reflux (VUR), renal parenchymal area, bladder morphology and dynamics by renal and bladder ultrasound, voiding cystourethrogram and urodynamic study, daytime continence, nocturnal polyuria, renal function, renal scarring by 99mTc-dimercaptosuccinic acid scan, febrile urinary tract infections (UTIs) and tolerability to OBD.RESULTSA total of 99 patients, 47 patients had OBD and 52 patients had no OBD, were included between September 2021 and August 2023. OBD showed significant improvement in HN, VUR, renal parenchymal area, bladder capacity, outline, detrusor overactivity, compliance, daytime continence and nocturnal polyuria. However, no significant difference was noted regarding bladder wall thickness, post-void residual urine, bladder sensation, detrusor leak point pressure, maximum flow rate, flow curve morphology, renal function, renal scarring and febrile UTIs. Tolerability to OBD was reported in 87%.CONCLUSIONSOBD, apart from patients' tolerability, improves HN, VUR, renal parenchymal growth, abnormal bladder morphology and dynamics, daytime continence and nocturnal polyuria that persist after EVA with no consequent renal function affection or febrile UTIs.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"19 1","pages":"101097JU0000000000005226"},"PeriodicalIF":0.0,"publicationDate":"2026-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148539228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updating of the AUA/ASTRO prostate cancer guidelines - a constant work in progress. 更新AUA/ASTRO前列腺癌指南-一项不断进行的工作。

The Journal of Urology Pub Date : 2026-07-17 DOI: 10.1097/ju.0000000000005225

Samir S Taneja

引用次数: 0

Diagnostic Test Characteristics of Renal Ultrasound Findings for High-Risk Bladder in Spina Bifida. 脊柱裂高危膀胱的肾超声诊断试验特点。

The Journal of Urology Pub Date : 2026-07-17 DOI: 10.1097/ju.0000000000005223

Luca A Morgantini,Danielle Herrera,Josephine Hirsch,Theresa Meyer,Lynn W Huang,Ilina Rosoklija,Diana K Bowen,Earl Y Cheng,Elizabeth B Yerkes,David I Chu

{"title":"Diagnostic Test Characteristics of Renal Ultrasound Findings for High-Risk Bladder in Spina Bifida.","authors":"Luca A Morgantini,Danielle Herrera,Josephine Hirsch,Theresa Meyer,Lynn W Huang,Ilina Rosoklija,Diana K Bowen,Earl Y Cheng,Elizabeth B Yerkes,David I Chu","doi":"10.1097/ju.0000000000005223","DOIUrl":"https://doi.org/10.1097/ju.0000000000005223","url":null,"abstract":"INTRODUCTIONSpina bifida (SB) can cause neurogenic bladder dysfunction and renal deterioration. Guidelines recommend renal ultrasound (RUS) for surveillance, but its utility in screening for high-risk bladder is unclear. We evaluated the performance of RUS findings for detecting high-risk bladder in youth with SB.MATERIALS AND METHODSWe conducted a retrospective cohort study of patients with myelomeningocele at a pediatric SB clinic who had a RUS within three months of urodynamic studies (UDS). RUS parameters included hydronephrosis, thinned parenchyma, hypoplasia, and scarring. High-risk bladder was defined as end-fill pressures/detrusor leak point pressures of 40 cmH2O or greater. We calculated sensitivity, specificity, and overall diagnostic accuracy (AUC) of RUS parameters for high-risk bladder, adjusting for repeat measurements. Various subgroup and sensitivity analyses were performed.RESULTSWe analyzed 575 UDS-RUS dyads from 244 unique patients. Median age was 7.2 years, 70% had ventricular shunts. 25% of dyads had high-risk bladder. Any hydronephrosis by Society for Fetal Urology (SFU) grading demonstrated an overall sensitivity 50%, specificity 57%, and clustered AUC of 55% for detecting high-risk bladder. RUS had similar performance across additional analyses, including non-ambulatory patients, high-grade hydronephrosis (SFU 3-4), any RUS abnormality, and using Urinary Tract Dilation (UTD) grading instead of SFU grading. Any hydronephrosis had higher test sensitivity for high-risk bladder in fuller bladders on RUS (RUS-bladder volume >75% of UDS-bladder capacity).CONCLUSIONRUS should not be used alone as a screening tool to identify high-risk bladder in youth with SB given its limited sensitivity and diagnostic utility. UDS remains an essential and necessary tool for surveilling at-risk bladders.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"25 1","pages":"101097JU0000000000005223"},"PeriodicalIF":0.0,"publicationDate":"2026-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer. 晚期前列腺癌：AUA/SUO指南修订（2026）第一部分：生化复发（局部治疗用尽后）和转移性激素敏感前列腺癌的评估和治疗。

The Journal of Urology Pub Date : 2026-07-16 DOI: 10.1097/ju.0000000000005220

Kristen R Scarpato,Michael S Cookson,Robert Dreicer,Mutlay Sayan,Alice Yu,Kristen E D'Anci,Lauren J Pak,Erin Kirkby

{"title":"Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026) Part I: Evaluation and Treatment of Biochemically Recurrent (Following Exhaustion of Local Therapy) and Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Kristen R Scarpato,Michael S Cookson,Robert Dreicer,Mutlay Sayan,Alice Yu,Kristen E D'Anci,Lauren J Pak,Erin Kirkby","doi":"10.1097/ju.0000000000005220","DOIUrl":"https://doi.org/10.1097/ju.0000000000005220","url":null,"abstract":"PURPOSEFollowing completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part I of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of biochemically recurrent (BCR) and metastatic hormone-sensitive prostate cancer (mHSPC).MATERIALS AND METHODSThe AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022 and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate.RESULTSThe Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein.CONCLUSIONSPart I of this Amendment provides updated guidance on imaging, germline and somatic testing, and evaluation and treatment of BCR following exhaustion of local therapy and mHSPC. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"232 1","pages":"101097JU0000000000005220"},"PeriodicalIF":0.0,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer. 晚期前列腺癌：AUA/SUO指南修订（2026）。第二部分：转移性去势抵抗性前列腺癌的评估和治疗。

The Journal of Urology Pub Date : 2026-07-16 DOI: 10.1097/ju.0000000000005219

Kristen R Scarpato,Michael S Cookson,Robert Dreicer,Mutlay Sayan,Alice Yu,Kristen E D'Anci,Lauren J Pak,Erin Kirkby

{"title":"Advanced Prostate Cancer: AUA/SUO Guideline Amendment (2026). Part II: Evaluation and Management of Metastatic Castration-Resistant Prostate Cancer.","authors":"Kristen R Scarpato,Michael S Cookson,Robert Dreicer,Mutlay Sayan,Alice Yu,Kristen E D'Anci,Lauren J Pak,Erin Kirkby","doi":"10.1097/ju.0000000000005219","DOIUrl":"https://doi.org/10.1097/ju.0000000000005219","url":null,"abstract":"PURPOSEFollowing completion of the 2025 Update Literature Review (ULR), the American Urological Association (AUA) incorporated new evidence generated since the 2023 publication of this Guideline via the AUA Amendment process. The summary presented herein represents Part II of the two-part series dedicated to addressing updated recommendations to provide a clinical framework for the evaluation and management of metastatic castration-resistant prostate cancer (mCRPC).MATERIALS AND METHODSThe AUA/SUO Advanced Prostate Cancer Guideline was reviewed via the AUA ULR process, which identified 38 studies for full-text review that were published between March 16, 2022 and August 26, 2025. Relevant studies were incorporated into the Guideline evidence base, and Guideline statements were updated as appropriate.RESULTSThe Panel developed evidence- and consensus-based statements based on an updated review to provide guidance on evaluation and management of advanced prostate cancer. These updates are detailed herein.CONCLUSIONSPart II of this Amendment provides new guidance on treatment of mCRPC and discusses future directions for the evaluation and management of advanced prostate cancer overall. Additional guidance regarding non-metastatic castration-resistant prostate cancer (nmCRPC) was deemed current following review. This Guideline will require further review as the diagnostic and treatment options in this space continue to evolve.","PeriodicalId":501636,"journal":{"name":"The Journal of Urology","volume":"25 1","pages":"101097JU0000000000005219"},"PeriodicalIF":0.0,"publicationDate":"2026-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148462326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0